Ameriprise
CLSD

Ameriprise’s Clearside Biomedical CLSD Stock Holding History

Ameriprise’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,569
Closed -$106K – 3955
2021
Q4 		$106K Buy
2,569
+33
+1% +$2.14K ﹤0.01% 3869
2021
Q3 		$228K Buy
+2,536
New +$224K ﹤0.01% 3671
2018
Q2 		– Sell
-4,853
Closed -$782K – 3646
2018
Q1 		$782K Buy
+4,853
New +$591K ﹤0.01% 3067

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's CLSD Position: Q1 2022 in Review

Ameriprise sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 2,569 shares — an estimated $106K sold.

Ameriprise first reported a position in CLSD in Q1 2018 and held it in 3 quarters. The position peaked at $782K in Q1 2018. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

  • Ameriprise reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
  • Ameriprise sold 2,569 Clearside Biomedical shares in Q1 2022, an estimated $106K.
  • Ameriprise first reported a position in Clearside Biomedical in Q1 2018 and held it in 3 quarters.
  • Ameriprise's Clearside Biomedical position peaked at $782K in Q1 2018.
  • 60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on Ameriprise's 13F filing for Q1 2022, filed 16 May 2022.